Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551789 | 0.84 | CCR1 (0.41) | ALDH1A1 | |
| SCHEMBL23551470 | 0.83 | CCR1 (0.43) | MAPT | |
| SCHEMBL23551374 | 0.76 | NAMPT (0.37) | — | |
| SCHEMBL3297347 | 0.67 | IDO1 (0.60) | DGAT1SOAT1IDO1 | |
| SCHEMBL3297351 | 0.67 | IDO1 (0.60) | DGAT1SOAT1IDO1 | |
| SCHEMBL462294 | 0.67 | ESR2 (0.62) | DGAT1FAAHCHRM2SOAT1DGAT2 | |
| SCHEMBL2259544 | 0.67 | ESR2 (0.62) | DGAT1FAAHCHRM2SOAT1DGAT2 | |
| SCHEMBL18763873 | 0.67 | ESR2 (0.62) | DGAT1FAAHCHRM2SOAT1DGAT2 | |
| SCHEMBL577535 | 0.67 | CYP2C9 (0.51) | DGAT1FAAHCHRM2SOAT1DGAT2 | |
| SCHEMBL3538810 | 0.67 | IDO1 (0.57) | DGAT1FAAHCHRM2SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |